Matchday Champions , a New Class of Mobile Football Game Now Available Worldwide; Kicks off With In-Game Event Hosted by Soccer Superstar Alexia Putellas and Mega Influencer Celine Dept
20.9.2024 14:00:00 EEST | Business Wire | Press release
Matchday, the developer of innovative mobile games for football’s five billion fans, has debuted its newest title, Matchday Champions. Today, the game is in early access globally, and it is celebrating with the limited-time “Copa Alexia x Céline,” a one-of-a-kind in-game tournament hosted by Spanish football World Cup Champion Alexia Putellas, and the immensely popular Belgian influencer Celine Dept.
Backed by Lionel Messi’s Play Time fund, Alexia Putellas, and other industry legends in sports and games, Matchday Champions is a one-of-its-kind experience. The game allows players to collect, craft and manage their own dream squad made up of both men's and women's players. It delivers the excitement of football using a cutting edge narrative creation engine, ensuring no two matches are ever the same. More than two million people have already pre-registered ahead of launch. Matchday Champions is now available in early access globally for iOS and Android phones.
Players who download the game can sign up to participate in the Copa Alexia x Céline, beginning on September 20. Hosted by World Cup champion, two-time Ballon d’Or winner and UEFA Women's Player of the Year Alexia Putellas and influencer Celine Dept, a football mega-fan with more than 50 million followers on YouTube, TikTok and Instagram, Copa Alexia x Céline challenges players to join Team Alexia or Team Celine, squaring off in a virtual tournament for bragging rights and prizes.
“Matchday is elevating two things I am very passionate about: women’s football and inclusivity,” said Putellas. “Women’s football has been on the rise for the last decade and Matchday’s co-gender football squads represent this reality in a fun and novel way for fans. I am honored to be a part of and shape a (virtual) football world that gives men and women truly equal footing. I hope the sort of representation we see in Matchday’s games will inspire the women’s football stars and all football fans of tomorrow, and help to drive forward conversations around equality.”
Licensed by FIFA and FIFPRO, Matchday offers fans the ability to collect digital player cards from tens of thousands of soccer athletes, and to combine both men’s and women’s players into their ideal squad to go head-to-head with other players’ teams. Players begin by assembling their squad, which they can start upgrading immediately. They then send their starting 11 onto the pitch, and Matchday Champions' proprietary simulation engine renders exciting in-game narratives. Play against rivals and friends while earning resources and recruiting footballers to improve their squad. Matchday Champions authentically captures the euphoria and heartbreak of real life football, and every match unfolds in a unique way.
“Football is an emotional experience for its five billion fans worldwide, and now they will be able to experience the drama of the sport in a video game that can seamlessly simulate games based on real players, real stats, and more,” said Sebastien de Halleux, Matchday co-founder and chief gaming officer. “Few players have experienced the emotional highs of football like Alexia Putellas, winning a World Cup, three UEFA Women's Champion Leagues, and 21 domestic trophies, along with all of her incredible individual accolades, so we’re honored that she has joined us not only as a Matchday ambassador but as the host of our first global in-game tournament.”
In Matchday Champions, players build and strengthen their squad, competing against others to move up through divisions and grow their club, competing with friends and Matchday’s vibrant global community, already numbering in the millions. Custom squads can be set up with ease through Matchday Champions' intuitive and accessible interface, allowing players to experiment with their team formation, as well as buy, sell and share cards with friends. Players hone their team in single player mode, then step on the pitch for a friendly match or an epic league competition with fans from all over the world. They can also join fans on the official Discord in discussing everything football, participate in weekly contests, participate in AMAs with football celebrities and follow real-world football matches.
Matchday continues to push the boundaries of digital ownership with Matchday Champions, which is part of a new category of sports games wherein fans build virtual squads by collecting digital cards of their favorite footballers. Players have true ownership of their cards and other digital items within Matchday Champions as they collect, trade and grow their dream team. These officially licensed cards can be utilized in all games within the Matchday ecosystem as it continues to grow.
Matchday previously launched the trivia and match prediction game Matchday Challenge: FIFA Women’s World Cup AU∙NZ∙2023™ Edition, which ran during FIFA Women’s World Cup and was played by millions of players all over the world.
Players can download Matchday Champions for free on the App Store or Google Play.
To learn more, please visit matchday.com, and join Matchday on X and Discord for the latest updates.
About Matchday
Matchday builds games for 5 billion football fans featuring officially licensed players and tournaments, in partnership with FIFA and FIFPRO. The company was founded by technology and gaming veterans who have successfully started and sold companies including Playfish (acq. EA), Glu Mobile (IPO), Hoodline (acq. Nextdoor), Spin (acq. Ford), and Viki (acq. Rakuten). Matchday is incubated by Leo Messi’s Play Time and backed by leading investors, with teams in San Francisco and Barcelona.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240920697449/en/
Contacts
Sibel Sunar
fortyseven communications for Matchday
matchday@fortyseven.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom